(Total Views: 527)
Posted On: 09/02/2022 8:08:54 PM
Post# of 148903
Re: LateToLearn #128339
Yes and no. I wouldn't say he is on a short leash.
I may be completely wrong, but I wouldn't say that Tanya has any pull at all.
In these calls, at least my impression of her, she doesn't seem all that domineering or Type "A" as you're suggesting. Nor does it appear that she is so dead set against any board member stepping outside their bounds. Rather, I feel Cyrus has free reign to speak at his volition and will speak when he feels the time / circumstances demand it. He may believe the shareholders have everything necessary to move the company forward based on the circulating understanding of the moment.
From 3/31/22 Conference Call:
6/30/22 Conference Call where Tanya is speaking.
Nothing here in suggests she wants to reduce communication to shareholders. It remains quite clear that Cyrus wants to " elucidate a DISCIPLINED go forward strategy and then EXECUTE on it ."
It appears to me that he is speaks softly, yet carries a big stick.
I may be completely wrong, but I wouldn't say that Tanya has any pull at all.
In these calls, at least my impression of her, she doesn't seem all that domineering or Type "A" as you're suggesting. Nor does it appear that she is so dead set against any board member stepping outside their bounds. Rather, I feel Cyrus has free reign to speak at his volition and will speak when he feels the time / circumstances demand it. He may believe the shareholders have everything necessary to move the company forward based on the circulating understanding of the moment.
From 3/31/22 Conference Call:
Quote:
Tanya Urbach, 5:00: 1) prioritizing the company's clinical development and regulatory objectives, 2) supplementing the board with professionals whose skill sets are synergistic with & serve to reinforce the breath of the boards existing capabilities and conducting a broad search for the company's next CEO; the board has worked closely with management to focus the company clinical development program to identify the potential to enhance that program and then to develop a program to further the progress of the clinical development program with a view towards commercialization of LL , 3) the board has worked and continues to work to identify and recruit highly qualified professionals directors, whose core competencies will serve to buttress capabilities of those already serving on the board , to that end, the company announced yesterday, subject to successful completion of her background check, the addition of the company's board of directors Dr. Karen J. Bronke PHD in microbiology, vp of corporate and business development at Jaguire Health, and she should be able to evaluate assets and consider the potential from both a biological and commercial standpoint. The board is also actively working to identify a financial expert as well as additional individuals capital markets & FDA regulatory expertise . The board has formed a CEO search committee working with 2 executive search firms as well as with corporate partners, to source and identify a ceo candidate. They are excited about the candidate pool.
6/30/22 Conference Call where Tanya is speaking.
Quote:
6:22 Thank you Antonio and Hello Everyone. Since our last call, the board has worked closely with executive management in an effort to refine the companies objective with an emphasis on those needs to be achieved in the short and medium terms. During this time, the company, led by the executive management team, has worked diligently and leveraged substantial resources in an effort to prepare the requisite deliverables for the FDA, with a view towards lifting the partial clinical hold in HIV and clinical hold in Covid 19. Other members of the board and I have been in frequent and direct communication with management , to understand the clinical hold and project management plan as it has been driven forward. Further, as we we have been working with management, to understand budgetary , with an emphasis on paths to achieving financial efficiency . And, we serve to support management , in its efforts to secure the recent financing. The board has also continued to interview potential candidates for the board of directors in an ongoing effort to supplement existing proficiencies with synergistic skills and thereby strengthen the boards overall capabilities . We have interviewed a number of potential candidates. It has been a pleasure to meet with such qualified and passionate professionals. We look forward to the opportunity to announce the addition of the Right talent.
The CEO search community has also been working since late January, to identify the critical attributes we thought in this companies next leader. We hoped to identify a well rounded leader who possessed several critical qualities, including a strong ethos , someone who would be dedicated to continuing the commitment to a strong and responsible corporate and government practices . With a view to further strengthening the companies credibility . We sought someone trained by big pharma, but with the ability to thrive in a more entrepreneurial environment. That person's strong operationally, and with a deep understanding of the science, a skilled communicator, capable of speaking to the companies stake holders, including the FDA, potential partners, vendors, and share holders like you.
We felt it important that the person have a strong physical discipline and the ability to identify and improve/recruit for any gaps in the companies management. The search committee also recognized that over the past several years, the company successfully developed substantial reliable data and identified several meaningful opportunities for its core technology, Leronlimab. Data in hand, we know CytoDyn needs to focus and prioritize resources on the best prospects for Leronlimab. With this understanding, the search committee was intent on identifying a well rounded leader, with the previously described attributes, but who also stood out as a exceptional strategic thinker from both a business and clinical perspective.
One candidate immediately separated himself from the competition. Particularly, with respect to thorough to the level of due diligence he brought to bear on the opportunity. He personally spent countless hours meeting with management in reviewing and assessing the data in an effort to understand leronlimab's potential, the business and the existing management core capability. Further, as he proceeded through his interview process, it became clear, that he is the embodiment of each of the attributes the committee sought and that's exactly what we believe this company needs to take it to its next level.
So, it is my true pleasure to announce that Dr. Cyrus Arman, PHD has been named President of CytoDyn. Dr. Arman is anticipated to advance to Chief Executive Officer and to join the companies Board of Directors within 6 months . During his initial term as president, Dr. Arman will devote substantial focus to the immediate operational needs of the company, and to further the developing and refining the companies strategic plans.
Antonio Migliarese, who has served as interim president as well as CFO since late January, will continue to serve as Chief Financial Officer. Dr. Arman employment with CytoDyn will begin July 9, 2022. Dr. Arman is reputed to be an exceptional 1st principle thinker, able to work to both scientific and commercial considerations to evaluate probabilities of success in sizing the market to develop different criteria's for forced ranking opportunities. Throughout his career, he has repeatedly led wargame events, where clients had to role play as their own competitors in an effort to understand how their decisions fit in the larger context of their market. He is known to be a quick learner, to be analytical and methodical in thought processes, a tireless worker and to have an incomparable sense of duty. The board could not be more excited about Dr. Arman's incoming leadership and he has our unanimous full support.
Dr. Arman most recently has served a Chief Business Officer for Nimble Therapeutics, a peptide therapeutics drug development company, where he was responsible for leading transactions, Finance acquisitions and corporate strategies. Dr. Arman has 15 years of experience in the corporate clinical and commercial strategies for bio technology companies including key level management and board of directors on strategy, transactional opportunities, financing and risk management. Dr. Arman's prior experience was as the vice president of corporate development and strategy at NEUVOGEN Inc. an early stage immuno-oncology company, where he was responsible for corporate development, business operations and corporate strategy functions. Prior to NEUVOGEN , he was a director in Amgen's corporate strategy unit. Dr. Arman began his career as a management consultant, where he advised clients in complex strategic projects involving and multibillion dollar business development investments and partnerships in both the biopharma and diagnostics sectors.
He has a MBA from University of California L.A., a PHD in neuroscience and MS in Biomedical engineering from USC and BS in biopsychology from University of California, San Diego Ca. About his impending start with the company, Dr. Arman said, "I am very excited to be joining CytoDyn. I believe the company has extremely promising prospects with Leronlimab that will benefit patients and create shareholder value. I look forward to working with the team to elucidate a disciplined go forward strategy and then execute on it." Finally, I would be remiss if I did not thank Antonio Migliarese for his capable and tireless leadership as our interim President."
So Thank you Antonio, and With that I will turn it back over to you.
Antonio's response is here at 14:01:
https://www.reddit.com/r/LeronLimab_Times/com...;context=3
Nothing here in suggests she wants to reduce communication to shareholders. It remains quite clear that Cyrus wants to " elucidate a DISCIPLINED go forward strategy and then EXECUTE on it ."
It appears to me that he is speaks softly, yet carries a big stick.
(1)
(0)Scroll down for more posts ▼
